Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
71.6M
-
Shares change
-
+5.8M
-
Total reported value, excl. options
-
$787M
-
Value change
-
+$44.3M
-
Put/Call ratio
-
0.34
-
Number of buys
-
88
-
Number of sells
-
-50
-
Price
-
$11.00
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q1 2023
168 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.6M shares
of 119M outstanding shares and own 60.03% of the company stock.
Largest 10 shareholders include FMR LLC (9.16M shares), Frazier Life Sciences Management, L.P. (8.68M shares), BlackRock Inc. (4.6M shares), STATE STREET CORP (3.61M shares), Rubric Capital Management LP (3.5M shares), Polar Capital Holdings Plc (3.14M shares), Bain Capital Life Sciences Investors, LLC (3M shares), VANGUARD GROUP INC (2.58M shares), MARSHALL WACE, LLP (2.31M shares), and JENNISON ASSOCIATES LLC (2.21M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.